RazorMetrics Secures Place in Inc. 5000 Fastest-Growing Companies for Second Year
RazorMetrics has recently announced its impressive ranking at No. 72 in the 2026 Inc. 5000 list, marking the second year in a row that the company has been recognized among the fastest-growing private companies in America. Not only does this placement highlight RazorMetrics' growth trajectory, but it also signifies the increasing demand for innovative solutions in the pharmacy technology sector. This year, RazorMetrics is proud to be listed in the top 2% of all companies assessed, reflecting its significant contribution to the healthcare industry, particularly in the area of pharmacy cost containment.
This recognition highlights RazorMetrics' position as a frontrunner in providing transformative solutions that optimize the prescription process. The company's strategic focus on reducing drug costs for both health plans and members has garnered attention from various stakeholders, including employers and pharmacy benefit managers (PBMs), who are eager to facilitate effective cost-savings without compromising patient care or provider efficiency.
Siva Mohan, MD, co-founder and chief medical officer of RazorMetrics, expressed pride in this achievement, emphasizing that the recognition mirrors the pressing need for affordable prescription solutions and the positive market reaction to RazorMetrics' model. The company has been providing essential insights that help to minimize avoidable spending in medication selection processes, ensuring that cost-effective alternatives are available to patients without disrupting the established workflows of healthcare providers.
This year has been particularly fruitful for RazorMetrics, with nearly $60 million in prescription drug savings reported in Florida alone. Other states have also seen significant financial impacts, with Ohio benefiting from over $11 million in savings, Texas accumulating $34 million, and Tennessee reporting $12 million. This data underscores the effectiveness of RazorMetrics' physician-directed pharmacy optimization model, which supports improved decision-making for approximately 1.7 million engaged physicians across the nation.
The continued demand for these types of solutions becomes even clearer when examining the findings of the 2026 State of Drug Access Survey conducted by RazorMetrics. The survey revealed that 84% of insured patients prefer their healthcare providers to suggest lower-cost medication options whenever clinically feasible. Yet, many still struggle with trust, access, and affordability issues at the pharmacy counter. The trends indicate a clear and growing need for solutions that identify unnecessary expenses early in the prescription process and facilitate better clinical prescribing decisions while also capturing savings effectively within existing healthcare practices.
Tom Dorsett, CEO and co-founder, highlighted that the growth of RazorMetrics goes beyond mere revenue; it reflects the company’s commitment to developing sustainable and effective pharmacy benefits across diverse populations and healthcare plans. He reiterated that the aim is to utilize innovative technology to enhance patient access to necessary medications while substantially lowering costs for members and organizations.
RazorMetrics’ recognition by Inc. is complemented by additional accolades over the past year, including honors from Deloitte and the American Business Awards, emphasizing the company's dedication to innovation in pharmacy cost management. These recognitions further solidify RazorMetrics' momentum in expanding its technological capabilities and reach within the industry.
Inc. determines its rankings based on revenue growth percentage over a three-year period. To qualify for the list, companies must meet specific criteria, including being privately held and independently operating without being subsidiaries of other businesses. RazorMetrics meets all these requirements while showcasing formidable growth from its founding date.
For more details on RazorMetrics’ groundbreaking solutions in pharmacy cost containment, visit www.razormetrics.com. To explore the full Inc. 5000 list and company profiles, visit www.inc.com.
This recognition highlights RazorMetrics' position as a frontrunner in providing transformative solutions that optimize the prescription process. The company's strategic focus on reducing drug costs for both health plans and members has garnered attention from various stakeholders, including employers and pharmacy benefit managers (PBMs), who are eager to facilitate effective cost-savings without compromising patient care or provider efficiency.
Siva Mohan, MD, co-founder and chief medical officer of RazorMetrics, expressed pride in this achievement, emphasizing that the recognition mirrors the pressing need for affordable prescription solutions and the positive market reaction to RazorMetrics' model. The company has been providing essential insights that help to minimize avoidable spending in medication selection processes, ensuring that cost-effective alternatives are available to patients without disrupting the established workflows of healthcare providers.
This year has been particularly fruitful for RazorMetrics, with nearly $60 million in prescription drug savings reported in Florida alone. Other states have also seen significant financial impacts, with Ohio benefiting from over $11 million in savings, Texas accumulating $34 million, and Tennessee reporting $12 million. This data underscores the effectiveness of RazorMetrics' physician-directed pharmacy optimization model, which supports improved decision-making for approximately 1.7 million engaged physicians across the nation.
The continued demand for these types of solutions becomes even clearer when examining the findings of the 2026 State of Drug Access Survey conducted by RazorMetrics. The survey revealed that 84% of insured patients prefer their healthcare providers to suggest lower-cost medication options whenever clinically feasible. Yet, many still struggle with trust, access, and affordability issues at the pharmacy counter. The trends indicate a clear and growing need for solutions that identify unnecessary expenses early in the prescription process and facilitate better clinical prescribing decisions while also capturing savings effectively within existing healthcare practices.
Tom Dorsett, CEO and co-founder, highlighted that the growth of RazorMetrics goes beyond mere revenue; it reflects the company’s commitment to developing sustainable and effective pharmacy benefits across diverse populations and healthcare plans. He reiterated that the aim is to utilize innovative technology to enhance patient access to necessary medications while substantially lowering costs for members and organizations.
RazorMetrics’ recognition by Inc. is complemented by additional accolades over the past year, including honors from Deloitte and the American Business Awards, emphasizing the company's dedication to innovation in pharmacy cost management. These recognitions further solidify RazorMetrics' momentum in expanding its technological capabilities and reach within the industry.
Inc. determines its rankings based on revenue growth percentage over a three-year period. To qualify for the list, companies must meet specific criteria, including being privately held and independently operating without being subsidiaries of other businesses. RazorMetrics meets all these requirements while showcasing formidable growth from its founding date.
For more details on RazorMetrics’ groundbreaking solutions in pharmacy cost containment, visit www.razormetrics.com. To explore the full Inc. 5000 list and company profiles, visit www.inc.com.
Topics Consumer Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.